Moderna, Inc. (MRNA) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The bar for Q2 is intentionally low — management guided revenue of $50–$100M and consensus sits at ~$105M — but the real question is whether the fall COVID/flu season setup and the mRNA-1010 flu PDUFA (August 5) can sustain the stock’s re-rating; the biggest swing factor is any signal on US COVID vaccination rates heading into the fall campaign.

Heading into Q2 2026 earnings, Moderna faces a deliberately de-risked bar: management guided Q2 revenue of $50–$100M (vs. $389M in Q1 driven by UK spring campaign deliveries), and consensus of ~$105M sits modestly above the midpoint, leaving limited room for a revenue beat to move the stock on its own. Management’s tone on the full year remains constructive — the company reiterated up to 10% revenue growth for FY2026 (~$2.09B consensus) — but the H2 weighting of that growth depends heavily on fall COVID vaccination rates and the timing of UK/Canada/Australia fall deliveries, both of which remain uncertain. Estimate revisions have been essentially flat since the Q1 print (Q2 consensus moved from $99M to $105M, FY from $2.085B to $2.088B), suggesting the Street is in a holding pattern rather than building conviction. The stock has rallied ~20% since Q1 earnings (from $45.37 to ~$54.49 as of July 29), driven almost entirely by multiple expansion on pipeline optionality — particularly the mRNA-1010 flu PDUFA on August 5 and the intismeran Phase 3 interim analysis expected in 2026 — rather than estimate revisions. The single biggest wildcard is the FDA’s decision on mRNA-1010: approval would make it Moderna’s fifth product and open the door to flu revenue in 2027, while a rejection or delay would likely unwind a meaningful portion of the recent re-rating.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a low absolute bar for Q2 revenue (~$105M vs. guided $50–$100M), but the operating loss per share (~−$1.89) is the bigger swing factor — cost execution and R&D spend timing will determine whether Moderna can narrow the cash burn faster than expected heading into the critical H2 season.

Table 1 — Current Quarter Snapshot (Q2 2026)

Sources: Visible Alpha Consensus and Actuals Data; Q1 2026 Earnings Call (May 1, 2026). Q2 2026 consensus as of July 30, 2026. Q1 2026 actuals are latest reported. Q2 2025 actuals are prior-year comparables.

Table 2 — Beat/Miss History (Last 8 Quarters)

Total Revenue

Operating EPS (Diluted)

Pattern: Moderna has beaten revenue consensus in 6 of the last 7 reported quarters, often by wide margins driven by international partnership delivery timing; the one miss (Q1 2025) was a low-revenue trough quarter. On operating EPS, the company has beaten in 5 of 7 quarters as cost reduction has consistently outpaced Street models. The Q2 2026 bar is set low enough that a revenue beat is likely, but the magnitude will be modest.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance is unchanged since the Q1 print — full-year revenue growth of up to 10% and ~$4.2B adjusted cash costs reiterated — but management’s tone has shifted more optimistic at Science Day (June 25), with increased conviction on the flu approval pathway and intismeran Phase 3 timing.

Sources: Q1 2026 Earnings Call (May 1, 2026); Moderna Science Day transcript (June 25, 2026); Visible Alpha Consensus and Actuals Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY2026 have been essentially flat since the Q1 print — Q2 revenue moved only +6% and FY revenue was unchanged — indicating the Street is not building in incremental upside ahead of the print. The gap between consensus and guidance midpoint on Q2 revenue (~+40%) reflects the Street pricing in modest upside to the guided range, not a high bar.

Estimates have been remarkably stable since the Q1 print, with no meaningful revision in either direction. The slight widening of FY2026 EPS consensus (−$7.06 to −$7.21) reflects modest cost-timing adjustments rather than a fundamental change in the outlook. The key catalyst for estimate revision will be Q2 revenue vs. guidance and any update on H2 COVID vaccination rate assumptions.

Source: Visible Alpha Consensus and Actuals Data (revision history table, weekly frequency, May 8 – July 30, 2026).

5. Stock Performance

Key Takeaway: MRNA has outperformed XBI (+28% vs. +16%) since Q1 earnings, driven almost entirely by multiple expansion on pipeline optionality (flu PDUFA, intismeran interim) rather than estimate revisions; the stock peaked at ~$82 in early July before pulling back ~33% to ~$54, suggesting the market is now pricing in a more balanced risk/reward ahead of the print.

Indexed Price Performance: MRNA vs. XBI vs. SPY (Since Q1 2026 Earnings, May 1, 2026)

Note: Indexed to 100 at May 1, 2026 close ($45.37 MRNA / $130.42 XBI / $720.65 SPY). Sector ETF: XBI (SPDR S&P Biotech ETF) — appropriate for Moderna’s biotech/vaccine sub-sector. MRNA peaked at ~$81.80 (Jul 6, indexed ~180) before pulling back ~33% to ~$54.49 (Jul 29). The stock’s outperformance vs. XBI is driven by pipeline-specific catalysts (flu PDUFA, intismeran), not broad biotech sentiment. Source: Yahoo Finance / Stock Price Data.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the FDA Advisory Committee’s positive vote on mRNA-1010 (flu vaccine) in mid-June, which catalyzed a ~40% stock rally and sets up the August 5 PDUFA as the single biggest near-term binary; the Sanofi patent lawsuit (July 15) is a new litigation overhang that adds uncertainty but is unlikely to affect Q2 results.

• June 17, 2026 — FDA Advisory Committee (VRBPAC) votes positively on mRNA-1010 (flu vaccine). Management cited the PAC vote as giving “good hope about the approval of flu moving forward.” PDUFA date is August 5, 2026. Implication: Approval would make mRNA-1010 Moderna’s fifth approved product and open the EU/US flu market for 2027 revenue; rejection would be a significant negative catalyst.
• June 25, 2026 — Moderna Science Day (Cambridge, MA). CEO reiterated 2028 cash breakeven guidance with “no change.” Highlighted mRNA-4194 Lynch syndrome Phase 1/2 study starting “this summer,” mRNA-6007 in vivo CAR-T advancing to clinic in 2027, and mRNA-2808 multiple myeloma data expected “later this year.” Intismeran Phase 3 interim confirmed for 2026. Implication: Reinforces pipeline depth and management confidence; no negative surprises.
• July 8, 2026 — Moderna appoints Michael McDonnell (former Biogen CFO) to Board of Directors and Audit Committee. McDonnell brings 35+ years of financial leadership including CFO roles at Biogen and IQVIA. Implication: Positive governance signal; adds financial credibility as Moderna prepares for multiple product launches and navigates path to 2028 breakeven.
• July 15, 2026 — Sanofi sues Pfizer and Moderna, alleging COVID-19 vaccines infringe Sanofi’s mRNA and LNP technology patents. Sanofi is seeking “fair compensation.” Implication: New litigation overhang on top of the recently settled Arbutus case ($950M lump sum due Q3 2026). Magnitude of exposure is unknown; unlikely to affect Q2 results but adds to long-term IP risk.
• May 1, 2026 — Q1 2026 Earnings: Arbutus/Genevant litigation settlement announced. $950M lump-sum payment due Q3 2026 ($878M recognized in Q1 COGS); potential additional payment of up to $1.3B pending Federal Circuit ruling on Section 1498 government contractor immunity (resolution expected late 2027/2028). Implication: Q3 cash will be materially impacted; watch for any update on the Federal Circuit timeline.
• May 11, 2026 — Moderna amends bylaws to designate federal courts for securities claims. Implication: Governance/legal housekeeping; not material for Q2 results.
• Ongoing — Intismeran (mRNA-4157/V940) Phase 3 adjuvant melanoma interim analysis. Event-driven; management confirmed “2026 seems the right time frame.” Five-year KEYNOTE-942 Phase 2b data presented at ASCO 2026 (oral abstract) showed sustained RFS benefit and encouraging OS trend. Implication: Interim readout is the single largest pipeline catalyst for the stock; early success would be transformative.
• Ongoing — Norovirus Phase 3 (fully enrolled, second NH season). Data expected in 2026 based on case accrual. Implication: Binary readout; positive data would validate Moderna’s infectious disease diversification beyond COVID.
• Ongoing — Propionic Acidemia (PA, mRNA-3927) pivotal study fully enrolled. Data expected later in 2026. Recordati commercialization partnership in place. Implication: First rare disease product approval would open a new revenue stream and validate the rare disease franchise.

7. Insider Transaction Activity

Key Takeaway: All three insider transactions since Q1 earnings are 10b5-1 planned sales — no discretionary open-market selling or buying. The President’s sale of 53,336 shares (~$3.6M) is the largest in dollar terms but is pre-planned and not a directional signal. No open-market buys have been filed.

All transactions are 10b5-1 pre-planned sales (transaction code S, disposition D). No open-market discretionary buys or sells have been filed since Q1 earnings. The absence of discretionary buying is notable given the stock’s pullback from its July peak, but the 10b5-1 nature of all sales means they carry no informational content about management’s near-term view. Source: SEC Form 4 Filings Database.

8. Peer Commentary — Current-Quarter Read-Through

Key Takeaway: Peer commentary from the last 60 days is consistently cautious on the COVID vaccine market (Pfizer, GSK) but constructive on the broader vaccine opportunity and mRNA technology (GSK); the most actionable read-through is Novavax/Sanofi’s COMPARE study showing Nuvaxovid’s tolerability advantage over Moderna’s next-gen COVID vaccine, which is a direct competitive headwind for mNEXSPIKE market share in the fall 2026 season.

Methodology: Only commentary from the last 60 days (on or after May 31, 2026) that addresses Q2 2026 conditions, forward seasonal vaccine demand, or the competitive landscape for the upcoming fall 2026 season is included. Retrospective commentary about prior-quarter results has been excluded. Each read-through is classified as Direct (explicitly about COVID/flu/RSV vaccine market dynamics affecting Moderna’s revenue) or Indirect (broader market/competitive/regulatory signals relevant to Moderna’s outlook).

8.1 Pfizer (PFE) — Goldman Sachs Healthcare Conference (June 8, 2026) & Jefferies Healthcare Conference (June 3, 2026)

Read-Through Type: Direct (COVID vaccine market sizing and uptake outlook for 2026)

• COVID vaccine market declining but stabilizing at a lower floor. Pfizer CEO Albert Bourla stated COVID vaccine revenue declined from $11B (2024) to $6.5B (2025) and is guided at $5B for 2026. He characterized vaccination rates as at a “lower level” and “not very variable,” suggesting the market has found a floor driven by motivated vaccinees (boosters for vulnerable populations) rather than broad uptake. Implication for MRNA: Confirms Moderna’s own assumption that US COVID vaccination rates will be soft in 2026; no upside surprise expected from the US market. The “floor” characterization is consistent with Moderna’s guidance that flat US vaccination rates would push revenue toward the high end of guidance.
• COVID treatment (not vaccine) is the variable. Bourla noted that COVID treatment demand is “highly correlated with the level of infection” and could swing materially depending on whether a COVID wave occurs in August/September 2026. Implication for MRNA: Moderna does not have a COVID treatment, so this is not a direct revenue read-through, but a COVID wave would also boost vaccine demand and could push Moderna’s fall season above guidance.
• Regulatory environment improving. Bourla noted that the erosion of trust in CDC vaccine recommendations in 2025 (pediatricians issuing their own guidelines) is “very rapidly moving to the right direction” with corrective actions initiated. Implication for MRNA: Improved regulatory trust and physician confidence in vaccine recommendations is a positive read-through for all vaccine makers, including Moderna’s COVID, RSV, and flu products.
• Pfizer’s strategic pivot to oncology reduces competitive intensity in vaccines. Bourla stated Pfizer “invested pretty much everything that we made from COVID to buy Seagen” and that oncology is the company’s primary strategic focus. Implication for MRNA: Pfizer’s reduced strategic emphasis on developing next-generation respiratory vaccines could reduce competitive pressure on Moderna in the flu and combination vaccine space, a modest positive.
• Pricing environment stabilized. Bourla noted that MFN pricing and geopolitical tensions that were “an existential threat” in 2025 are “behind us for the moment,” with 17 identical deals negotiated by the industry. Implication for MRNA: A stable pricing environment supports Moderna’s revenue assumptions for its strategic partnership contracts and reduces the risk of pricing pressure on its vaccine portfolio.

8.2 Novavax (NVAX) via Sanofi Partnership — Jefferies Healthcare Conference (June 4, 2026)

Read-Through Type: Direct (COVID vaccine competitive dynamics for fall 2026 season; combination vaccine pipeline)

• COMPARE study: Nuvaxovid shows favorable tolerability vs. Moderna’s next-gen COVID vaccine. Novavax management highlighted that the COMPARE study “just read out” showing a “favorable safety profile of Nuvaxovid versus the next-gen from Moderna.” Sanofi plans to “lean in with this COMPARE data” in marketing for the fall 2026/2027 season, targeting both consumer and physician audiences. Implication for MRNA: This is the most direct and actionable competitive read-through. Sanofi will actively market Nuvaxovid’s tolerability advantage against mNEXSPIKE in the fall 2026 season. This could pressure Moderna’s market share gains, particularly among side-effect-sensitive patients and physicians. Management should be asked about the COMPARE data on the Q2 call.
• Sanofi is preparing aggressively for the fall 2026 COVID season. Sanofi is “obviously getting ready for the season this year” and is expected to take a “methodical approach” to building the Nuvaxovid market, analogous to how they built their flu franchise. Implication for MRNA: Sanofi’s well-funded and strategic marketing push will intensify competition in the COVID vaccine market, potentially limiting Moderna’s ability to gain market share with mNEXSPIKE.
• Sanofi’s combination COVID+flu (CIC) program advancing rapidly. Sanofi presented positive Phase 1/2 CIC data at its R&D Day (December 2025) and is in “active dialogue with regulatory agencies” in the US and Europe, anticipating “launching into a pivotal program for one or both” CIC programs. Sanofi designated CIC as one of its “big 3” future growth drivers. Implication for MRNA: Sanofi’s accelerated CIC program is a direct competitive threat to Moderna’s mCOMBRIAX (already EU-approved) and the US combination filing pathway. Moderna’s first-mover advantage in EU combination vaccines may be challenged by Sanofi’s scale and flu market dominance.
• Sanofi’s flu market dominance (~2/3 share in 50+ enhanced segment) is a structural advantage. The combined COVID+flu market is ~$12B, with Sanofi holding ~$2.5–$3B in flu net sales and nearly 2/3 market share in the premium 50+ segment. Implication for MRNA: Moderna’s mRNA-1010 flu vaccine (PDUFA August 5) will enter a market where Sanofi has entrenched relationships with physicians and payers in the exact demographic Moderna is targeting (enhanced/high-dose segment for older adults). This is a structural competitive headwind for flu market share capture.

8.3 GSK — Q2 2026 Earnings Call (July 28, 2026)

Read-Through Type: Direct (RSV vaccine market; flu vaccine mRNA technology validation) and Indirect (broader vaccine market sentiment)

• RSV vaccine market growing: Arexvy tender win in Australia. GSK reported vaccine growth of +8% in Q2 2026, with Arexvy (RSV) benefiting from a two-year supply tender win in Australia. Implication for MRNA: Validates continued RSV market demand and the importance of tender/procurement wins in international markets. Moderna’s mRESVIA is approved in the US, EU, and Canada but is not expected to be a significant 2026 growth driver; the GSK data confirms the market exists but also that competition for tenders is intensifying.
• GSK validates mRNA technology for next-generation flu vaccines. GSK explicitly stated it believes “there’s an opportunity using our mRNA technology to establish benefit over current standard of care” for flu and announced it will present “positive Phase 2 results” at the Options meeting. GSK cited flu vaccine effectiveness varying from 20–60% over 15 seasons as a “true unmet need.” Implication for MRNA: GSK’s validation of mRNA for flu is a positive read-through for Moderna’s mRNA-1010 investment thesis. However, it also signals that GSK will be a future competitor in the mRNA flu space, adding to the long-term competitive landscape.
• Physician recommendation drives vaccine uptake 40% → 80%. GSK’s Head of Global Vaccines Commercial noted that a strong physician recommendation doubles willingness to vaccinate (40% to 80%), and an expanded indication (e.g., cardiovascular or dementia benefit) increases physician confidence to recommend from 50% to 90%. GSK explicitly stated it will “be looking at what that means in terms of price” if broader benefit data are positive. Implication for MRNA: Reinforces the importance of physician engagement and label expansion for Moderna’s vaccine portfolio. If mRNA-1010 or mNEXSPIKE can demonstrate broader protective effects, there is meaningful pricing upside.
• Post-COVID hangover and political headwinds are short-term pressures. GSK’s Chief Commercial Officer characterized the vaccine business as “under short-term pressure, frankly, because of politics in some locations and a post-COVID hangover,” while emphasizing the long-term durability and high barriers to entry. Implication for MRNA: Consistent with Moderna’s own characterization of the US COVID market; confirms that the headwinds are industry-wide and not Moderna-specific. The long-term durability framing supports Moderna’s 2027–2028 growth narrative.
• Softer inhaled respiratory market demand in Q2. GSK noted “softer inhaled respiratory market demand” in Q2 but expects improvement in H2. Implication for MRNA: Indirect read-through; softer respiratory market sentiment in Q2 is consistent with the seasonal trough for COVID/flu vaccines and does not change the H2 outlook.

Summary Read-Through Table

Sources: Pfizer Goldman Sachs Global Healthcare Conference transcript (June 8, 2026); Pfizer Jefferies Global Healthcare Conference transcript (June 3, 2026); Novavax Jefferies Global Healthcare Conference transcript (June 4, 2026); GSK Q2 2026 Earnings Call transcript (July 28, 2026). All commentary is from the last 60 days and addresses Q2 2026 conditions or forward seasonal vaccine demand. Retrospective prior-quarter commentary has been excluded.

Key Questions for the Q2 2026 Earnings Call

1. Q2 revenue vs. guidance: Did revenue come in above the $50–$100M guided range, and what drove the delta (US vs. international mix)?
2. Fall 2026 COVID season setup: What are management’s current assumptions for US COVID vaccination rates in H2, and has the outlook changed since Q1?
3. mRNA-1010 flu PDUFA (August 5): Any update on FDA interactions or label expectations? What is the commercial launch plan if approved?
4. COMPARE study response: How does management respond to Sanofi’s marketing of Nuvaxovid’s tolerability advantage vs. mNEXSPIKE? What is the competitive positioning strategy?
5. Arbutus Q3 cash payment: Confirm the $950M lump-sum payment timing and updated YE 2026 cash guidance.
6. Intismeran Phase 3 interim: Any update on event accrual pace and timing of the interim analysis?
7. 2027 cost guidance update: Management previously guided $3.5–$3.9B for 2027 cash costs; any refinement?